Isolated respiratory tract microorganisms and clinical characteristics in asthma exacerbation of obese patients: a multicenter study

Table 2 Prescribed medications for asthma maintenance therapy and the level of asthma control at the time of asthma exacerbation

	Total	No obesity	Obesity	P
	n = 381^*	n = 216	n = 165	P
Prescribed respiratory medicines
ICS + LABA	186 (48.8)	102 (47.2)	84 (50.9)	0.476
ICS	26 (6.8)	14 (6.5)	12 (7.3)	0.762
LAMA	4 (1.0)	2 (0.9)	2 (1.2)	0.786
LAMA + LABA	3 (0.8)	3 (1.4)	0	0.262
ICS + LABA + LAMA	56 (14.7)	37 (17.1)	19 (11.5)	0.125
No treatment	106 (27.8)	58 (26.9)	48 (29.1)	0.629
LTRA	185 (48.8)	103 (47.7)	82 (50.3)	0.613
Oral steroid	46 (12.1)	28 (13.0)	18 (11.0)	0.571
Biologics	6 (1.6)	5 (2.3)	1 (0.6)	0.243
Level of controls^*,†				0.208
Uncontrolled	85/239 (35.6)	39/128 (30.5)	46/111 (41.4)	0.077
Partly controlled	101/239 (42.3)	58/128 (45.3)	43/111 (38.7)	0.305
Well controlled	53/239 (22.2)	31/128 (24.2)	22/111 (19.8)	0.414

Data are shown as n (%) per each group
*Not all the medication records or the level of asthma control were investigated because one of 24 medical institutions only allowed to a portion of their medical records. The denominator refers to the number of patients investigated
^†The level of asthma control within 3 months before the episode of AE
ICS, inhaled corticosteroid; LABA, long-acting beta-agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist

ISSN: 1471-2466